Greater Anxiety Linked With Unmet Information Needs in Precancerous Oral Lesions
the Cancer Therapy Advisor take:
Greater anxiety levels were associated with high degrees of unmet information need in patients with precancerous oral lesions, according to an article published online in the European Journal of Cancer Care.
Participants in this study included 106 individuals seen at the otolaryngology outpatient department at a single medical center in central Taiwan for precancerous oral lesions. The patients completed structured questionnaires that aimed to measure their state anxiety levels, attitudes towards cancer prevention, and need for information.
Results showed the most common unmet information needs among the patients were about obtaining their test results promptly.
Furthermore, higher levels of unmet information needs were more common in patients with precancerous oral lesions who reported high levels of state anxiety, had a long duration of time since quitting betel nut chewing, and had no history of oral cancer.
Patients with unmet information needs were more likely to have higher levels of anxiety about precancerous lesions than those who had their information needs met.
The study suggests improvements be made in health education and individual counseling in order to satisfy information needs of patients.
Greater anxiety levels were associated with high degrees of unmet information need in patients with precancerous oral lesions.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Opinion: Understanding the FDA's Take on Cannabidiol
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer